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Background. Peripheral arterial disease (PAD) is often associated with risk factors including cigarette smoking, hyperten-
sion and hypercholesterolaemia, and patients have a high risk of future vascular events. Good medical management results
in improved outcomes and quality of life, but previous studies have documented sub-optimal treatment of risk factors. We
assessed the management of cardiovascular risk factors in patients with PAD referred to specialist vascular clinics.
Methods. This was a prospective, protocol driven registry carried out in UK vascular clinics. Patients who were first-time
referrals for evaluation of PAD were eligible if they had claudication plus ankle-brachial pressure index (ABPI) 0.9.
Statistical associations between key demographic and treatment variables were explored using a chi-squared test.
Results. We enrolled 473 patients from 23 sites. Mean age was 68 years (SD 10) and 66% were male. Mean estimated
claudication distance was 100 m, and ABPI was 0.74. Mean systolic blood pressure (SBP) was 155 mmHg, and 42%
had a SBP >160 mmHg. Forty percent were current smokers and half had tried to give up in the prior 6 months, but there
was no evidence of a systematic method of smoking cessation. Mean total cholesterol was 5.4 (SD1.2) mmol/l and 30% had
levels >6 mmol/l. Antiplatelet therapy had been given to 70% and statins to 44%. Prior CHD was present in 29% and
these patients had significantly higher use of antiplatelet therapy, statins and ACE-inhibitors.
Conclusions. In spite of attempts to raise awareness about PAD as an important marker of cardiovascular risk, patients
are still poorly treated prior to referral to a vascular clinic. In particular, the use of evidence-based treatments is sub-
optimal, while hypertension and cigarette smoking are poorly managed. More work needs to be done to educate health
professionals about the detection and optimal medical management of PAD.
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Peripheral arterial disease (PAD) is a common and im-
portant manifestation of atherosclerosis. PAD affects
about 5% of western populations aged between 55
and 74 years and usually presents with intermittent
claudication (IC).1,2 IC can usually be managed con-
servatively with only 5e10% of patients requiring
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plasty or amputation) within 5 years of presentation.
Patients with PAD are at increased risk of coronary
and cerebrovascular events, and more than half of pa-
tients with PAD have significant co-existing coronary
disease.3 The risk of cardiac death in patents with IC
is 3e4 times greater than those without IC, and ac-
counts for as many as 75% of all deaths in patients
with IC.4,5 Classical risk factors such as smoking,
hypertension, hypercholesterolaemia and diabetes are
common in patients with PAD and require the same
aggressive treatment as patients with coronary or
cerebrovascular disease.2,6
Previous studies have shown that PAD is poorly
managed in terms of providing evidence basedrved.
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anti-platelet agents, statins, anti-hypertensives and
smoking cessation.7e10 The reasons for this under-
treatment are not completely clear, but appear to be
related to a poor understanding of the increased car-
diovascular risk associated with PAD, leading to an
underestimation of the serious nature of the disease.11
Over the past few years there has been a concerted ef-
fort by professional organisations to raise awareness
of PAD, its associated risks and the need for proper
management. It is uncertain if these efforts have led
to adequate improvements in PAD management in
primary and secondary care.12 We undertook the Pro-
spective Registry of Peripheral Arterial Risks, Events
and Distribution (PREPARED-UK) of patients re-
ferred from primary care to specialist vascular clinics
to understand how they had been treated prior to
referral. Since all patients had IC as part of the entry
criteria for the registry our assumption was that the
treatments on referral provided information on the
management of symptomatic PAD in primary care.
We report on the baseline characteristics and treat-
ments of these patients. This information may provide
a benchmark by which future practice may be
improved.
Methods
PREPARED-UK is a prospective cohort study de-
signed to assess characteristics, treatments and out-
comes of patients with IC presenting for the first
time to Vascular Units in the UK. Follow-up of pa-
tients for 2 years is ongoing and will be reported sep-
arately, as will information on Quality of Life and
health economics. The UK Multi-Centre Research
Ethics committee approved the study protocol, pa-
tient information sheet and consent form, and these
documents were then approved by Local Research
Ethics Committees in the participating institutions.
Patients were required to give written informed con-
sent before their participation. Patients were also reg-
istered, with their consent, with the Office of National
Statistics (ONS) for long-term follow-up.
Study design
A list of members of the Vascular Surgical Society of
Great Britain and Ireland was obtained and names
were sorted by NHS region. We wished to include
25 sites in the study each enrolling 20 consecutive pa-
tients. For each region we selected at random a name
from the regional centre and 3 additional vascular
units in that region. If centres or particularinvestigators were unable to take part we continued
to invite other centres until we had enough centres
to take part. Potentially eligible patients with IC
were identified through vascular out-patient clinics
of the participating hospitals. Participating centres
were recognized to have vascular expertise and had
access to treadmill testing, duplex scanning, diagnos-
tic and interventional radiology, CT scans, and mag-
netic resonance imaging (MRI). Two of the centres
were running nurse-led claudication clinics. One dis-
trict hospital had no vascular laboratory while MRI
was not available in another.
Eligibility
Patients were eligible if they had a good clinical his-
tory of IC occurring within a walking distance of
about 400 metres or quarter of a mile, had an ankle/
brachial blood pressure index 0.9, were presenting
as a new referral to a vascular clinic of a participating
hospital and were able to provide written informed
consent. Patients were excluded if they presented
with critical limb ischaemia including rest pain,
necrosis or ulceration, spinal canal claudication or
venous claudication, or if the claudication was inci-
dental to presentation with another major medical
condition. Claudication distance was based on pa-
tients estimates not on treadmill testing. A current
smoker was defined as smoking within the previous
3 months, and an ex-smoker as a history of smoking
but not within 3 months of enrolment. No assess-
ments of cotinine levels or carbon monoxide were car-
ried out as part of this study. Clinical assessments and
blood test results for biochemistry, haematology and
lipid profile were performed as part of routine proce-
dures and not as a specific part of the registry proto-
col. They were performed in the local laboratories of
the collaborating hospitals. Hence these results are
not available for all patients.
Study management
A Steering Committee designed and agreed the pro-
tocol and the case record forms. The study was co-
ordinated by the Clinical Trials and Evaluation Unit
of the Royal Brompton Hospital, London, and the
Northern Vascular Unit, Freeman Hospital and Uni-
versity of Newcastle, Newcastle. Centres were trained
on study procedures by telephone call and were
instructed to identify consecutive eligible patients
presenting to the outpatient clinic. Case report forms
were completed and any queries ormissing data points
were resolved by direct contact with the centre.Eur J Vasc Endovasc Surg Vol 33, April 2007
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This report is of baseline data of the study, and themain
aimwas to explore associations betweendemographics
and treatments. The study planned to follow patients
up for a minimum of two years. We estimated that the
rate of death, stroke,myocardial andmajor limb ampu-
tation would be about 5% per annum or 10% over
2 years. A pragmatic sample size assumption would
allow comparisons between major subgroups to (e.g.
men and women, or prior CHD and no prior CHD).
With a sample size of 500 we could detect absolute dif-
ferences in clinical outcomes of 10% between major
subgroups with an alpha error of 5% and beta error of
20% (80% power). We estimated that this sample size
would also provide sufficient power to explore associ-
ations of age, gender and other important baseline de-
mographic variables on the symptoms and signs of
IC, andwhether treatmentwas influenced by these var-
iables. Variableswere described asmeans and standard
deviations, or proportions, as appropriate. The main
pre-specified subgroup comparison was between pa-
tients with and without a history of coronary heart dis-
ease (CHD) defined as one or more of the following:
prior myocardial infarction (MI), angina, coronary ar-
tery bypass grafting (CABG) or percutaneous coronary
intervention (PCI). These groupswere comparedby the
Student’s t-test or the chi squared test as appropriate.
Other baseline variables of interest were: age, gender,
ankle-brachial pressure index (ABPI), systolic blood
pressure (SBP), diabetes, hypertension, absolute clau-
dication distance, smoking, antiplatelet and lipid
lowering medication. Statistical associations wereEur J Vasc Endovasc Surg Vol 33, April 2007explored using a chi-squared test, splitting continuous
variables into two or more categories as required.
Results
Participating centres
Forty-two centres were invited to take part of which
23 agreed to participate. A total of 473 patients were
enrolled between June 2002 September 2003. Nineteen
centres enrolled 10 or more patients. The maximum
number enrolled at a single centre was 51 and the av-
erage per centre was 21 patients. Since some centres
enrolled fewer than the 20 patients requested, other
centres were requested to enrol more patients in order
to reach the pre-specified sample size of 500 patients.
Although the intention was to enrol consecutive eligi-
ble patients, it seems that a number of centres were
not able to achieve this.
Patient demographics and risk factors
The main demographic characteristics of enrolled
subjects are given in Table 1. Mean age was 68 (SD
10) years and 66% were male. Mean systolic blood
pressure was 155 (SD 24) mmHg, and 54% were being
treated for hypertension. Systolic blood pressure
>140 mmHg was recorded in 76%, and 42% had
SBP >160 mmHg. Twenty percent had a history of
prior diabetes (with 5% treated with insulin), 29%
had a history of prior coronary artery disease and
20% were working at the time of enrolment.Table 1. Baseline characteristics
Characteristic Females, N¼ 159 Males, N¼ 319 p-value N¼ 478*
Age at enrolment, mean (SD) (min e max) 69.7 (9.6) (40, 87) 66.7 (9.6) (34, 93) 0.001 68 (9.7) (34, 93)
BMI, mean (SD) (min e max) 26.2 (4.6) (17, 42) 26.7 (4.3) (17, 40) 0.22 26.5 (4.4) (17, 42)
Systolic blood pressure, mean (SD) (min e max) 157.4 (25.2) (90, 220) 153.3 (22.7) (75, 234) 0.08 154.7 (23.6) (75, 234)
<100 mmHg [n(%)] 1 (1) 2 (1) 0.71 3 (1)
100e140 mmHg [n(%)] 37 (23) 75 (24) 112 (23)
140e160 mmHg [n(%)] 47 (29) 113 (35) 160 (34)
160e180 mmHg [n(%)] 46 (29) 80 (25) 126 (26)
>180 mmHg [n(%)] 28 (18) 48 (15) 76 (16)
Diastolic blood pressure, mean (SD) (min e max) 80.8 (11.4) (90, 110) 82.5 (12.4) (50, 130) 0.16 81.9 (12.1) (50,130)
History of diabetes, n(%) Non insulin dependent 16 (10) 56 (18) 0.031 72 (15)
Insulin dependent, n(%) 9 (6) 15 (5) 0.65 24 (5)
History of Hypertension n(%) 100 (63) 165 (52) 0.021 265 (55)
History of Hyperlipidaemia n(%) 67 (42) 139 (44) 0.77 206 (43)
Angina n(%) 28 (18) 59 (19) 0.81 87 (18)
Prior myocardial infarction (MI) n(%) 18 (11) 51 (16) 0.17 69 (14)
Prior coronary artery bypass graft (CABG) n(%) 10 (6) 34 (11) 0.12 44 (9)
Prior percutaneous coronary intervention (PCI) n(%) 6 (4) 11 (3) 0.86 17 (4)
Any prior coronary heart disease (angina, MI, CABG or PCI) 41 (26) 100 (31) 0.21 141 (29)
Prior cerebrovascular accident (CVA) n(%) 10 (6) 25 (8) 0.54 35 (7)
In paid employment n(%) 15 (9) 79 (25) <0.001 94 (20)
*This is the total number of patients with baseline information. The denominator for each variable ranges from 460 to 473.
Significant values are in bold.
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The mean estimated initial claudication distance
(walking distance from start at which the symptoms
appeared) was 100 m (interquartile range [IQR] 50e
200 m) and mean estimated absolute claudication
distance (point at which patient could walk no more
and had to rest) was 150 m (IQR 75e250 m) (Table 2).
Overall mean ABPI was 0.74, with slightly but non
significantly lower values in the left leg compared to
the right. Fifty three percent reported symptoms of
claudication in both legs.
Smoking status
A history of smoking was present in 84% (39% current
smokers and 45% ex-smokers), and in those that gave
a history of smoking, estimated mean pack years
smoked was 40 (Table 2). About 50% of smokers had
attempted to stop smoking in the previous six
months, and of the methods used, nicotine replace-
ment therapy and ‘‘will power’’ (i.e. attempting to
give up without external help or using nicotine
replacement therapy) were the most common.
Medications
Seventy percent of patients were on antiplatelet ther-
apy at enrolment and most were taking aspirin at
a mean dose of 75 mg, which is the standard dosage
used in the UK for cardiovascular risk reduction. Clo-
pidogrel was used in 5% of patients (Table 4). The
most common reason for not taking an antiplatelet
agent was because it had never been prescribed. Forty
four percent were taking a statin, 26% an ACE inhib-
itor, 18% a beta-blocker, and 29% were on a diuretic.
Results of blood tests
Cholesterol measurements were available for 73%
of patients. Mean total cholesterol was 5.4 mmol/L(SD 1.2), and 31% had values 6 mmol/L. Other
blood results including other lipid parameters, glucose
levels and creatinine are given in Table 5.
Comparison of patients with prior CHD versus
no prior CHD
Patients with a prior CHD history were significantly
older, had a greater proportion of diabetes and hyper-
tension, but fewer were current smokers, than those
without a history of prior CHD (Table 6). Proportions
of CHD patients taking antiplatelets, statins, ACE in-
hibitors and beta blockers were significantly higher.
There was better control of blood pressure among
CHD patients as measured by a significantly greater
proportion with systolic blood pressure <140 mmHg.
Associations between baseline variables
Apart from the pre-specified subgroup of patients
with CHD, other exploratory analyses between base-
line variables were undertaken. Differences between
men and women are highlighted in Tables 1e6. The
main differences include (all p< 0.01): women are
older, have less paid employment, are more likely to
be non smokers. Decreasing ABPI showed a significant
association with older age ( p¼ 0.01), higher systolic
blood pressure ( p¼ 0.03), and decreased absolute
claudication distance ( p¼ 0.03). Antiplatelet and lipid
lowering therapies were more frequently prescribed
in older patients ( p< 0.01), those with higher systolic
blood pressure ( p¼ 0.01), diabetes ( p¼ 0.01), hyper-
tension ( p< 0.01) and smokers ( p< 0.01).
Discussion
Our findings confirm that in spite of attempts to raise
awareness about PAD as an important marker of car-
diovascular risk, patients are still poorly managed
prior to referral to a vascular clinic. About one third
do not receive antiplatelet treatment, half do notTable 2. Features of claudication
Characteristic Females Males p-value N¼ 478
Initial claudication distance (m) Median (IQR)* 80 (40, 182) 100 (50, 200) 0.031 100 (50, 200)
Absolute claudication distance (m) Median (IQR)* 110 (70, 210) 80 (150, 300) 0.013 150 (75, 250)
Ankle brachial pressure index: Left, mean (SD) 0.72 (0.19) 0.71 (0.22) 0.93 0.72 (0.21)
Ankle brachial pressure index: Right, mean (SD) 0.74 (0.19) 0.75 (0.22) 0.48 0.75 (0.21)
Bilateral claudication n(%) 92 (58) 165 (52) 0.21 257 (54)
Previous vascular graft n(%) 1 (1) 8 (3) 0.15 9 (2)
Documented internal carotid stenosis (>50%), n(%) 3 (2) 11 (3) 0.34 14 (3)
Known Aortic aneurysm n(%) 4 (3) 9 (3) 0.85 13 (3)
*Distances estimated by patients and investigators, hence ‘‘rounding off’’ is likely.
IQR¼ inter quartile range.Eur J Vasc Endovasc Surg Vol 33, April 2007
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Description Females Males p-value N¼ 478
Smoking, n(%)
Current 62 (39) 123 (38) <0.001 185 (39)
Ex-smoker1 56 (35) 165 (52) 221 (46)
Non-smoker 41 (26) 16 (5) 57 (12)
Smoker other (e.g. pipe/cigars) 0 (0) 15 (5) 15 (3)
Pack years smoked, Median (IQR)2 37 (21, 50) 40 (30, 60) 0.003 40 (26, 55)
Attempted to stop in last 6 months, n(%)3 39/71 (55) 71/145 (49) 0.41 110/216 (51)
Method used by the 110 patients, n(%)
Nicotine replacement therapy 25 (64) 22 (31) 0.003 47 (43)
Bupropion 3 (8) 2 (3) 0.23 5 (5)
Counselling 3 (8) 7 (10) 0.39 10 (9)
Other: 13 (33) 43 (61) 0.006 56 (51)
Will power or no specific method 10 (26) 42 (59) 0.001 52 (47)
Hypnosis 3 (8) 1 (1) 0.13 4 (4)
1 Ex smoker¼ prior smoking who has given up >3 months prior to enrolment.
2 Among those who are current or ex-smokers. 379 patients available for analysis.
3 Among those who are current or ex-smokers. 211 patients available for analysis.receive lipid-lowering agents and three quarters do
not receive ACE-inhibitors or angiotensin-II antago-
nists in spite of clear evidence supporting the routine
use of these agents in patients with PAD.13e16 There is
concomitant poor management of blood pressure and
cholesterol. About 40% of the cohort were current
smokers and about half of these have tried to give
up within the previous 6 months, but there did not
appear to be any systematic approach to the provision
of smoking cessation therapies. As expected there
were high rates of conventional cardiovascular risk
factors and about one third had a history of co-existing
coronary heart disease. The latter group were much
better treated with antiplatelet, cholesterol lowering
and anti-hypertensive treatments. We also found sig-
nificant associations between ABPI and age, systolic
blood pressure and absolute claudication distance.
The benefits of optimally managed hypertension
are well established and a low ABPI appears to be
an important predictor of morbidity and mortality in
the elderly with systolic hypertension.17,18 In our
study 76% of patients had a systolic BP> 140 mmHg
and 32% had systolic BP> 160 mmHg. This finding
is worrying since systolic hypertension has shown to
be linked with the risk of both MI and stroke in the
elderly and in patients with PAD, and this risk can
be reduced by appropriate treatment.19 Many hyper-
tensive claudicants will require at least two blood-
pressure-lowering drugs to achieve and maintain
recommended blood pressure targets (140/
85 mmHg), and compliance is a major problem.20
Treatment with an ACE inhibitor has been shown to
reduce the risk of major cardiovascular events in pa-
tients with clinical as well as subclinical PAD.21 Both
the HOPE study and more recently the ASCOT trial
have reported on subgroups of patients with PADEur J Vasc Endovasc Surg Vol 33, April 2007and shown that they obtain the same benefit as other
groups of patients with cardiovascular disease with-
out an increase in adverse event rates.13,21,22 There
is little evidence that Beta-blockers should be
Table 4. Medications
Description Females Males p-
value
N¼ 478*
(%)
Antiplatelet therapy 107 (67) 228 (71) 0.35 335 (70)
Types of antiplatelet
(n¼ 335)
Aspirin 101 (94) 216 (95) 0.64 317 (95)
Clopidogrel 6 (6) 12 (5) 0.72 18 (5)
Dipyridamole 4 (4) 7 (3) 0.69 11 (3)
Mean dose
of Aspirin (mg)
85 90 0.37 89
Reason for not taking
antiplatelet n¼ 143
52 (33) 91 (29)
History of peptic
ulcer or gastritis
6 (12) 8 (9) 0.28 14 (10)
Indigestion 6 (12) 3 (3) 9 (6)
Allergy 0 (0) 1 (1) 1 (1)
Never prescribed/
recommended
29 (56) 65 (71) 94 (66)
Non-compliance 2 (4) 2 (2) 4 (3)
Taking Warfarin 0 (0) 0 (0) 0 (0)
Other 9 (17) 12 (13) 21 (15)
Statin 69 (43) 143 (45) 0.77 212 (44)
Lipid lowering
agent (other)
2 (1) 4 (1) 0.99 6 (1)
Warfarin 7 (4) 10 (3) 0.48 17 (4)
Digoxin 5 (3) 10 (3) 0.99 15 (3)
ACE Inhibitor 41 (26) 82 (26) 0.98 123 (26)
Beta blocker 36 (23) 49 (15) 0.05 85 (18)
Calcium antagonist 42 (26) 66 (21) 0.16 108 (23)
Angiotensin II
antagonist
17 (11) 15 (5) 0.01 32 (7)
Nitrate 21 (13) 34 (11) 0.41 55 (12)
Quinine 13 (8) 12 (4) 0.04 25 (5)
Diuretic 64 (40) 74 (23) <0.001 138 (29)
Oral hypoglycaemic 12 (8) 46 (14) 0.03 58 (12)
Insulin 9 (6) 17 (5) 0.88 26 (5)
*The denominator varies from 469 to 473 due to some variables with
missing values.
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Description Females Males p-value N¼ 478*
Cholesterol result available n(%) 122 (77) 229 (72) 0.25 351 (73)
Total cholesterol, mean (SD) mmol/L 5.67 (0.11) 5.28 (0.08) 0.004 5.4 (1.2)
<4 mmol/L [n(%)] 9 (7) 29 (13) 0.036 38 (11)
4e5 mmol/L [n(%)] 23 (19) 68 (30) 91 (26)
5e6 mmol/L [n(%)] 46 (38) 70 (30) 116 (33)
6e7 mmol/L [n(%)] 26 (21) 43 (19) 69 (20)
>7 mmol/L [n(%)] 18 (15) 19 (8) 37 (10)
HDL, median (IQR) n¼ 180 1.5 (1.3, 1.8) 1.3 (1.1, 1.5) <0.001 1.4 (0.6)
LDL, median (IQR) n¼ 112 3.1 (2.5, 3.7) 3.2 (2.3, 4) 0.97 3.2 (1.0)
Triglycerides, Median (IQR) n¼ 266 1.68 (1.27, 2.50) 1.84 (1.25, 2.85) 0.48 1.7 (1.3, 2.7)
Glucose, Median (IQR) mmol/L n¼ 265 5.1 (4.8, 5.7) 5.5 (4.9, 6.4) 0.04 5.3 (4.8, 6.1)
<5 mmol/L [n(%)] 32 (38) 52 (29) 0.28 84 (32)
5e7 mmol/L [n(%)] 41 (48) 89 (50) 130 (49)
7e10 mmol/L [n(%)] 7 (8) 22 (12) 29 (11)
10e14 mmol/L [n(%)] 2 (2) 13 (7) 15 (6)
>14 mmol/L [n(%)] 3 (4) 4 (2) 7 (2)
Creatinine, mean (SD) mmol/L n¼ 323 90.4 (22.9) 102.9 (28.5) <0.001 98.9 (27.4)
<60 mmol/L [n(%)] 6 (6) 3 (1) 0.03 9 (3)
60e100 mmol/L [n(%)] 64 (61) 121 (55) 185 (57)
100e120 mmol/L [n(%)] 26 (25) 60 (27) 86 (26)
120e150 mmol/L [n(%)] 7 (7) 21 (10) 28 (9)
>150 mmol/L [n(%)] 1 (1) 14 (7) 15 (5)
Haemoglobin, mean (SD) n¼ 304 13.5 (1.5) 14.6 (1.4) <0.001 14.2 (1.5)
MCV, mean (SD) n¼ 291 91.2 (5.5) 91.9 (6.6) 0.37 91.6 (6.3)
Platelets, mean (SD) n¼ 304 283.2 (74.9) 255 (85.8) 0.005 264.5 (83.3)
White cell count, mean (SD) n¼ 302 8.3 (2.2) 8.3 (1.9) 0.96 8.3 (1.9)
CRP, Median (IQR) n¼ 68 5 (5, 7) 5 (5, 6) 0.42 5 (5, 6.5)
*Blood tests were carried out according to local protocols, hence not all 473 patients had results available for analysis.specifically avoided in PAD for reasons relating to
worsening claudication or precipitating severe
ischaemia.6,23
Smoking is one of the strongest risk factors for the
development of PAD, for progression of disease and
a poor outcome.6,24e27 The 5-year mortality rate for
patients with IC who continue to smoke is 40% to
50%.28 Smoking cessation has been shown to not
only reduce disease progression but also the mortality
in PAD.29,30 In our study about 40% were current
smokers in contrast to the Euroheart survey of CHD
patients <70 years in which 21% reported smoking.31
Half of the smokers in our study reported trying to
give up within 6 months of entry, but a surprising
finding was that only a half of those who reported try-
ing to give up had been offered nicotine replacement
therapy or smoking cessation counselling. Given that
smoking is intrinsically linked to PAD in most pa-
tients, much of the risk reduction strategy should be
directed to smoking cessation. Likewise the PART-
NERS programme found only half of patients with
PAD who smoked were prescribed interventions for
smoking cessation, indicating a missed opportunity
for prevention.29 It has been shown that smokers are
more likely to succeed with the help and support
from healthcare professionals, and that combining
nicotine replacement therapy and brief advice can
improve long-term cessation rates.32,33 The UKNationalInstitute of Clinical Excellence (NICE) has approved
nicotine replacement therapy as cost-effective and
recommended that it should be offered to all patients
making a serious attempt to stop smoking.34
In the current study we also found that there was
a strong association between prior CHD history and
an increased probability that patients were on anti-
platelet therapy, lipid lowering agents, ACE inhibitors
or b-blockers. About one third of patients with IC
have evidence of coronary and/or cerebrovascular
disease.35,36 It appears that patients with PAD and
CHD patients are better treated than those with
PAD alone suggesting that use of evidence based
treatments in cardiology is better than for PAD. This
may be due in part to CHD management being
heavily influenced by specialist clinics, whereas PAD
is largely managed in primary care.
The most common reason for a patient not being
on an antiplatelet agent was that it had never been
prescribed or recommended. This is despite good
evidence that the use of an antiplatelet agent reduces
the risk of future cardiovascular events and death by
about 25% in PAD.16,37 There is evidence from the
large CAPRIE study, that clopidogrel reduces the risk
of death stroke and MI in patients with cardiovascular
disease including PAD more effectively than aspirin.38
A Consensus Report, which reviewed all the available
evidence for antiplatelet therapy in PAD, concludedEur J Vasc Endovasc Surg Vol 33, April 2007
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PAD with aspirin as first line treatment, and clopido-
grel providing a useful alternative if aspirin was not
tolerated.15 The CHARISMA trial of 15,000 patients
with elevated vascular risk randomised to aspirin
alone or aspirin plus clopidogrel, has not show any
convincing evidence for dual antiplatelet therapy in
patients with PAD.39
Only about half the patients were taking a statin.
Evidence for the benefit of statins in patients with
CHD has been available for a number of years, but
specific evidence for PAD patients has been largely
lacking because they were not included in the large
randomised trials. However, in the Scandinavian
Simvastatin Survival Study, simvastatin significantly
reduced the incidence of new claudication in patients
with prior MI or angina.40 In addition simvastatin and
atorvastatin have been shown to improve pain free
walking in claudicants.41,42 Clear evidence of the ben-
efit of statins has now been confirmed in patients with
Table 6. Comparison of patients with prior CHD history (Prior MI,
angina, CABG or PTCA) versus those with no prior CHD history
Prior CHD No Prior CHD p-value
N¼ 141 N¼ 337
Age Mean (SD) 69 (8.6) 67 (10.1) 0.012
N (%) in subgroups by age
<60 year 20 (14) 88 (26) 0.011
60e<70 46 (33) 108 (32)
70 75 (53) 141 (42)
Sex (% male) 100 (71) 219 (65) 0.21
APBI mean (SD) 0.73 (0.17) 0.73 (0.17) 0.70
<0.63 37 (27) 89 (27) 0.60
0.63e<0.75 33 (24) 61 (19)
0.75e<0.85 34 (25) 93 (29)
0.85 34 (25) 83 (25)
Blood Pressure:
Mean SBP (SD) 151 (24.5) 156 (23.1) 0.044
Mean DBP (SD) 80.2 (12.1) 82.7 (12.0) 0.042
SBP< 140 47 (34) 68 (20) 0.002
SBP 140 93 (66) 269 (80)
Diabetes (%) 39 (38) 57 (17) 0.007
Hypertension (%) 107 (76) 158 (47) <0.001
Smoking
Current 35 (25) 150 (45) <0.001
Ex-smoker 81 (57) 140 (42)
Non-smoker 22 (16) 35 (10)
Other 3 (2) 12 (4)
Mean (SD) total
cholesterol level (mmol/l)
5.1 (1.0) 5.6 (1.3) 0.001
Antiplatelet (%) 123 (87) 212 (63) <0.001
Lipid lowering
(statin or other) (%)
98 (70) 117 (35) <0.001
ACE inhibitor (%) 54 (38) 69 (20) <0.001
Beta blocker (%) 50 (35) 35 (10) <0.001
Angiotensin II antagonist (%) 8 (6) 24 (7) 0.56
1. Patients with one or more of the following features: prior myocar-
dial infarction (MI), angina, coronary artery bypass grafting (CABG)
or percutaneous coronary intervention (PCI).
2. P values for multiple subgroups (e.g. for age, ABPI, SBP and
smoking) are for global comparisons.
3. Calculated from the mean of ABPI from right and left leg.Eur J Vasc Endovasc Surg Vol 33, April 2007PAD, as well as other groups at risk of cardiovascular
events, in the large Heart Protection Study of 20,000
patients which was published during the course of
enrolment for our study14, and the meta-analysis of
cholesterol lowering trials.43 The low use of statins
is reflected by high cholesterol levels found, with
over 50% having a cholesterol greater than 5 mmol/L.
ABPI showed significant associations with older
age, blood pressure and claudication distance. The
usefulness of ABPI as a marker of generalised athero-
sclerosis is well documented and a number of cohort
studies have reported a graded inverse relationship of
decreasing ankle-brachial index to cardiovascular
events.44,45 There are concerns that ABPI is not a rou-
tine measurement apart from in vascular clinics, even
though the majority of detection and management of
PAD is done in the primary care setting. Calls for
wider screening to detect PAD in at risk populations
(elderly, diabetics and those with other vascular risk
factors) have been made and this may require more
training and resources directed to health professionals
in primary care.12 As expected the mean age of
women was higher than men, more men smoked
and more men were in paid employment.
Our study has a number of limitations. We used
a pragmatic design in order to minimise extra work
in busy vascular clinics. Patients enrolled were not
selected at random from referring practices, and in
some of the participating centres, they were not con-
secutive referrals. For these and other reasons general-
ising our results to wide populations of PAD patients
in the UK and other countries may need to be done
with caution. We used information from routine blood
results and as a consequence there was missing infor-
mation, and no central checking of laboratory values.
Smoking history was obtained from patients without
independent checks using cotinine levels, but previ-
ous studies have shown that information on smoking
history provided by patients is generally reliable.
Our study provides current evidence that the med-
ical management of patients with PAD still needs
improvement.46,47 Evidence in our study from those
patients with co-existing CHD confirms that high
rates of preventive treatment can be used in this pop-
ulation given the right motivation and knowledge.
Improved blood pressure and cholesterol control,
a systematic approach to smoking cessation and other
lifestyle changes including exercise and appropriate
diets, will help to improve the outlook of patients
with PAD.46,47 In the UK it seems unlikely that vascu-
lar surgical clinics will have the resources to deliver
this care in its entirety, although this might be possible
in other European countries. It is recommended that
patients with PAD should be followed up in units
449Characteristics and Treatments of Patients with PAD Referred to UK Vascular Clinicsthat specialize in vascular care and management of
cardiovascular risk factors. These messages must be
delivered as a matter of urgency to health profes-
sionals diagnosing and managing PAD in primary
care, those responsible for health care planning policy,
and society at large.
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